Polycystic Ovary Syndrome Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Polycystic Ovary Syndrome remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 752 matched trial records and 152 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07698925 | Intervention not normalized | Not Applicable; Recruiting | Cairo University | Egypt | Pittsburgh Sleep Quality Index (PSQI) (Pre-treatment at baseline of the study Post-treatment after intervention…) | 2026-09-01 |
| NCT07687264 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Zurich | Switzerland | Change in Normalized Relative Plasma Metabolite Abundance From Baseline to 2 Hours Post-Glucose Ingestion (Baseline (fasting, Visit 2) and 2 hours post-glucose ingestion (Visit 2).); Change in Normalized Relative Plasma Protein Abundance From Baseline to 2 Hours Post-Glucose Ingestion (Baseline (fasting, Visit 2) and 2 hours post-glucose ingestion (Visit 2).) | 2029-07-30 |
| NCT07687667 | GLP-1 agonist (Nxera Pharma) | Not Applicable; Not yet recruiting | Peking University Third Hospital | China | Ongoing Pregnancy Rate (First cycle of IVF/ICSI-ET (the first frozen-thawed embryo transfer cycle if…) | 2028-12-01 |
| ChiCTR2600127495 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | China | Fasting blood glucose, 30-minute blood glucose, 60-minute blood glucose, 120-minute blood glucose, 180-minute blood glucose (Initial consultation); Kidney deficiency and liver depression syndrome, kidney deficiency and blood stasis syndrome, spleen deficiency and phlegm-dampness syndrome, and phlegm-blood stasis syndrome (Initial consultation) | 2026-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- 1815-P: Efficacy and Safety of the GlP-1/GIP Dual Agonist HRS9531 in Overweight/Obese Chinese Patients with Polycystic Ovary Syndrome (Phase 2): the indexed record reports Menstrual frequency = 0.76 episode/12 weeks; Menstrual frequency = 1.11 episode/12 weeks.
- Phase 2A, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Women With Polycystic Ovary Syndrome (PCOS) (Phase 2): the indexed record reports Hepatic Fat Content(Least Squares Mean) = -0.3499 percentage of liver fat (Standard Error, 1.06137); Hepatic Fat Content(Least Squares Mean): P-Value = 0.0613; Hepatic Fat Content(Least Squares Mean): P-Value = 0.0613.
- Treating PCOS With Semaglutide vs Active Lifestyle Intervention (Phase 2/3): the indexed record reports Change in Hepatic Fat Fraction(Mean) = -1.41 Change in percentage of liver fat (Standard Deviation, 2.24); -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including GLP-1 agonist (Nxera Pharma) (Discovery; GLP-1R). Company & Deal Intelligence records identify sponsor context for Cairo University, University of Zurich, Peking University Third Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Polycystic Ovary Syndrome has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
